An FDA Advisory Committee recommended the approval of dapagliflozin.
FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in AdultsBusiness Wire Dec 12
AstraZeneca and Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-1 that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
4:11 am AstraZeneca (<a href="http://feeds.finance.yahoo.com/q?s=azn" name="azn">AZN</a>) and Bristol-Myers Squibb (<a href="http://feeds.finance.yahoo.com/q?s=bmy" name="bmy">BMY</a>) announced the FDA recommends the investigational medicine metreleptin for the treatment of pediatric and aDec 12
By a lopsided vote of 13 to 1, an independent committee of medical experts voted on Thursday to recommend approval of a new type of diabetes drug from Bristol-Myers Squibb that U.S. regulators rejected two years ago due to safety concerns. The advisory panel to the U.S. Food and Drug Administration said the benefits of the medicine, called dapaglifozin, appear to outweigh its risks. Bristol-Myers is developing the drug, which is already approved in Europe, in partnership with AstraZeneca Plc (NYSE: AZN - news) . The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
A diabetes pill from Bristol-Myers Squibb Co. and AstraZeneca Plc won the backing of U.S. advisers, moving the drug closer to becoming the second in a new class of medicines to treat the disease.
A Wall Street Transcript Top 10 Portfolio Manager Interview of 2013 with Finny Kuruvilla, M.D., Ph.D., the Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript Dec 12
67 WALL STREET, New York - December 12, 2013 - The Wall Street Transcript has just published its Top Ten Portfolio Manager Interviews of 2013 Report. This special feature contains expert industry commentary ...
Continuing our countdown of the 12 Foolish Days of Christmas, today we're looking at 10 stocks yielding 5% or greater that have the cash flow and growth potential to sustain these beefy annual payouts.
Goldman sad Genpact's deal to provide financing and accounting services to AstraZeneca indicates the deal environment is improving and that Genpact is making progress getting through the pipeline.
4 Biotechs On the Move Today
AstraZeneca and Bristol-Myers announced that the EMDAC has voted in favor of approving metreleptin.
AstraZeneca, Fifth Street Finance, Potash and HollyFrontier: High dividend, low beta and little debt reward long-term investors.
Myriad Genetics entered into a cancer research collaboration with Janssen Research & Development, LLC.
30 captivating facts about a biotech breakthrough